Frequently Asked Questions about M-M-R®II

M-M-R®II is a vaccine indicated for active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age or older. The first dose of M-M-R®II is administered at 12 to 15 months of age and the second dose of M-M-R®II is administered at 4 to 6 years of age.

Frequently Asked Questions about M-M-R®II

What is the indication and usage for M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live)?

M-M-R®II is a vaccine indicated for active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age or older.

The first dose of M-M-R®II is administered at 12 to 15 months of age and the second dose of M-M-R®II is administered at 4 to 6 years of age.

What is the recommended dosing for M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live)?

The first dose is administered at 12 to 15 months of age. A second dose is administered at 4 to 6 years of age. Each 0.5 mL dose is administered subcutaneously.

What is the Selected Safety Information for M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live)?

Selected Safety Information

  • M-M-R®II is contraindicated in certain individuals, including those with: a history of hypersensitivity to any component of the vaccine, including gelatin; a history of anaphylactic reaction to neomycin; individuals who are immunodeficient or immunosuppressed due to disease or medical therapy; an active febrile illness; active untreated tuberculosis; or those who are pregnant or are planning to become pregnant within the next month.
  • Due caution should be employed in administration of M-M-R®II to persons with: a history of febrile seizure or family history of febrile seizures; immediate-type hypersensitivity reactions to eggs; thrombocytopenia.
  • Vaccination should be deferred in individuals with a family history of congenital or hereditary immunodeficiency until the individual’s immune status has been evaluated and the individual has been found to be immunocompetent.
  • Immune globulins (IG) and other blood products should not be given concurrently with M-M-R®II. The ACIP has specific recommendations for intervals between administration of antibody-containing products and live virus vaccines.
  • The following adverse reactions have been identified during clinical trials or reported during post-approval use of M-M-R®II or its components: fever, headache, dizziness, rash, injection-site reactions, febrile convulsions, anaphylaxis and anaphylactoid reactions, arthritis, thrombocytopenia, encephalitis, and encephalopathy.

Dosage and Administration

  • FOR SUBCUTANEOUS USE ONLY.
  • M-M-R®II vaccine can be administered concurrently with other live viral vaccines.  If not given concurrently, M-M-R®II vaccine should be given one month before or one month after administration of other live viral vaccines to avoid potential for immune interference.

Before administering M-M-R®II, please read the accompanying Prescribing Information. The Patient Information also is available.


What are the side effects of the M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live) Vaccine?

The most common side effect of vaccination with M-M-R®II is pain at the site of injection. Other side effects may include:

  • Fever
  • Rash

Less common side effects may also include:

  • Swelling of the testicles
  • Joint pain and/or swelling

Some side effects are rare but may be serious:

  • Difficulty breathing, wheezing, hives, or a skin rash may be signs of an allergic reaction
  • Bleeding or bruising under the skin
  • Seizures, a severe headache, a change in behavior or consciousness, or difficulty walking.

To report SUSPECTED ADVERSE REACTIONS, contact Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., at 1-877-888-4231 or VAERS at 1-800-822-7967 or www.vaers.hhs.gov.

Is the Measles, Mumps and Rubella (MMR) vaccine available for adults?

M-M-R®II is indicated for individuals 12 months of age and older.

What are the Contraindications for the M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live) Vaccine?

  • Hypersensitivity to any component of the vaccine
  • Immunosuppression
  • Moderate or severe febrile illness
  • Active untreated tuberculosis
  • Pregnancy

Does the M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live) Vaccine require a booster?

No. Each 0.5 mL dose is administered subcutaneously. The first dose is administered at 12 to 15 months of age. A second dose is administered at 4 to 6 years of age.

How effective is the M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live) Vaccine?

Efficacy of measles, mumps, and rubella vaccines was established in a series of double-blind controlled trials. For additional information please refer to the M-M-R®II Prescribing Information.

How is the M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live) Vaccine administered?

M-M-R®II is administered by a subcutaneous injection.

What are the storage guidelines for M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live)?

Storage Temperature Range

  • To maintain potency, M-M-R®II must be stored between -58°F and +46°F (-50°C to +8°C). Use of dry ice may subject M-M-R®II to temperatures colder than -58°F (-50°C).

Temperature Range Prior to Reconstitution

  • Before reconstitution, refrigerate the lyophilized vaccine at 36°F to 46°F (2°C to 8°C).

Light Exposure

  • Exposure to light may inactivate the vaccine viruses.

Guidelines for Reconstituted Vaccine

  • Administer M-M-R®II vaccine as soon as possible after reconstitution. If not administered immediately, reconstituted vaccine may be stored between 36°F to 46°F (2°C to 8°C), protected from light, for up to 8 hours. Discard reconstituted vaccine if it is not used within 8 hours.

Diluent Storage Temperature

  • Store accompanying diluent in the refrigerator (36°F to 46°F, 2°C to 8°C) or at room temperature (68°F to 77°F, 20°C to 25°C). Do not freeze the diluent.

For information regarding the product or questions regarding storage conditions, call 1-800-MERCK-90 (1-800-637-2590).

For more information on vaccine storage and handling, please visit www.vaccinestorageandhandling.com to review the guidelines and help ensure your practice’s compliance.

What is the Difference Between MMR and M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live)?

MMR vaccine is a common term used to refer to the vaccine that helps protect against measles, mumps, and rubella. M-M-R®II is Merck’s MMR vaccine.

What are the ingredients in M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live)?

Active Ingredients: weakened forms of the measles, mumps, and rubella viruses.

Inactive Ingredients: sorbitol, sucrose, hydrolyzed gelatin, recombinant human albumin, trace amounts of fetal bovine serum, other buffer and media ingredients, neomycin.

Is M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live) available for children through the Vaccines For Children (VFC) program?

Yes, in most states, M-M-R®II is available through the Vaccines for Children (VFC) program for children who qualify. Check with your state or local VFC program to learn more about the specific products available to your practice.

What is the CPT Code for M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live)?

The CPT Code for M-M-R®II is 90710.

What is the NDC code for M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live)?

NDC 0006-4681-00.

How can I order M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live) for my practice?

M-M-R®II can be ordered via ordering.merckvaccines.com, by calling into the Merck Vaccines Customer Care line 877.VAX.MERCK (877.829.6372), or through your preferred wholesaler/distributor. For a list of Merck authorized distributors please go to Authorized distributors – Merck.com.

What are the CDC Guidelines for M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live) Routine Vaccination Schedule?

The CDC Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger specifies routine vaccination for measles, mumps, and rubella and varicella vaccination is a 2-dose series at 12–15 months, and 4–6 years. Dose 2 may be administered as early as 4 weeks after dose 1 of a measles-containing vaccine.

What is the CDC Recommended Catch-up Vaccination Schedule for Measles, Mumps, and Rubella?

The CDC recommended catch-up schedule for unvaccinated children and adolescents is a 2-dose series at least 4 weeks apart.

How long has M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live) been available for use in the United States?

M-M-R®II was initially approved for use in the U.S. in 1978.

vaers

You are about to leave MerckVaccines.com

Vaccine Adverse Event Reporting System

Thank you for visiting.

Merck does not review or control the content at the site to which this link connects. Merck makes no representation with respect to the content of any non-Merck site.

vacStorage

You are about to leave MerckVaccines.com

Thank you for visiting.

Merck does not review or control the content at the site to which this link connects. Merck makes no representation with respect to the content of any non-Merck site.

authDis

You are about to leave MerckVaccines.com

Thank you for visiting.

Merck does not review or control the content at the site to which this link connects. Merck makes no representation with respect to the content of any non-Merck site.

Indications and Usage for M-M-R®II

  • M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live) is a vaccine indicated for active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age or older.
  • The first dose of M-M-R®II is administered at 12 to 15 months of age and the second dose of M-M-R®II is administered at 4 to 6 years of age.

M-M-R®II is contraindicated in certain individuals, including those with: a history of hypersensitivity to any component of the vaccine, including gelatin; a history of anaphylactic reaction to neomycin; individuals who are immunodeficient or immunosuppressed due to disease or medical therapy; an active febrile illness; active untreated tuberculosis; or those who are pregnant or are planning to become pregnant within the next month.

  • M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live) is contraindicated in certain individuals, including those with: a history of hypersensitivity to any component of the vaccine, including gelatin; a history of anaphylactic reaction to neomycin; individuals who are immunodeficient or immunosuppressed due to disease or medical therapy; an active febrile illness; active untreated tuberculosis; or those who are pregnant or are planning to become pregnant within the next month.
  • Due caution should be employed in administration of M-M-R®II to persons with: a history of febrile seizure or family history of febrile seizures; immediate-type hypersensitivity reactions to eggs; thrombocytopenia.
  • Vaccination should be deferred in individuals with a family history of congenital or hereditary immunodeficiency until the individual’s immune status has been evaluated and the individual has been found to be immunocompetent.
  • Immune globulins (IG) and other blood products should not be given concurrently with M-M-R®II. The ACIP has specific recommendations for intervals between administration of antibody-containing products and live virus vaccines.
  • The following adverse reactions have been identified during clinical trials or reported during post-approval use of M-M-R®II or its components: fever, headache, dizziness, rash, injection-site reactions, febrile convulsions, anaphylaxis and anaphylactoid reactions, arthritis, thrombocytopenia, encephalitis and encephalopathy.

DOSAGE AND ADMINISTRATION

  • FOR SUBCUTANEOUS USE ONLY.
  • M-M-R®II vaccine can be administered concurrently with other live viral vaccines. If not given concurrently, M-M-R®II vaccine should be given one month before or one month after administration of other live viral vaccines to avoid potential for immune interference.

Before administering M-M-R®II, please read the accompanying Prescribing Information. The Patient Information also is available.

  • M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live) is a vaccine indicated for active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age or older.
  • The first dose of M-M-R®II is administered at 12 to 15 months of age and the second dose of M-M-R®II is administered at 4 to 6 years of age.
vaxRef

You are about to leave MerckVaccines.com

Vaxelis

Thank you for visiting.


US-MMR-00121 10/21